Stephanie Woodall

Stephanie Woodall

Company: KSQ Therapeautics

Job title: Director, Head of Quality

Seminars:

Workshop A – Developing an Analytical Genotoxicity Package: From Preclinical Development Through Drug Product Release & Beyond 9:00 am

A new generation of gene modified TIL therapy is on the horizon for patients, with genome editing approaches now being commonly employed as means to enhance TIL activity and persistence in the hostile microenvironment of solid tumors. Since genome editing may increase genotoxicity risk, and due to the importance of complying with an evolving regulatory…Read more

day: Pre-Conference Day

© Copyright 2022 Hanson Wade | Design and site by Event Engine | Hanson Wade Limited is registered in England & Wales, number 06752216.
Registered Office: Suite A, 6 Honduras Street, London EC1Y 0TH.